Renal Division, Department of Medicine IV, University Hospital of the Ludwig Maximilian University, Munich, Germany.
Nat Rev Nephrol. 2022 Jul;18(7):415-416. doi: 10.1038/s41581-022-00581-0.
Targeting type I interferon immune responses is a potential strategy for the treatment of systemic lupus erythematosus. Although a phase 2 clinical trial of anifrolumab did not meet its primary end point, further studies are needed to assess the effects of interferon blockade on flare rates of lupus nephritis. However, the observed higher risk of herpes zoster associated with anifrolumab use suggests that caution is warranted with this strategy.
针对 I 型干扰素免疫反应是治疗系统性红斑狼疮的一种潜在策略。虽然 anifrolumab 的 2 期临床试验未达到主要终点，但仍需要进一步研究来评估干扰素阻断对狼疮肾炎发作率的影响。然而，anifrolumab 治疗相关的疱疹性疾病发生率增加提示在应用这种策略时需要谨慎。
